Hutchin Hill Capital’s AbbVie ABBV Stock Holding History

Hutchin Hill Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-750,000	Closed	-$225K	–	535
2014 Q3	$225K	Buy	+750,000	New	+$41.6M	0.01%	535

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Hutchin Hill Capital's ABBV Position: Q3 2017 in Review

Hutchin Hill Capital sold out of AbbVie (ABBV) in Q3 2017, closing a stake of 30,000 shares — an estimated $2.17M sold.

Hutchin Hill Capital first reported a position in ABBV in Q1 2014 and held it in 7 quarters. The position peaked at $52.4M in Q4 2014. 1,798 funds tracked by Wall St. Rank hold ABBV as of Q3 2017.

Hutchin Hill Capital reported no remaining AbbVie position as of Q3 2017 after selling out during the quarter.
Hutchin Hill Capital sold 30,000 AbbVie shares in Q3 2017, an estimated $2.17M.
Hutchin Hill Capital first reported a position in AbbVie in Q1 2014 and held it in 7 quarters.
Hutchin Hill Capital's AbbVie position peaked at $52.4M in Q4 2014.
1,798 funds tracked by Wall St. Rank held AbbVie as of Q3 2017.

Based on Hutchin Hill Capital's 13F filing for Q3 2017, filed 14 Nov 2017.